Please note that Sartorius Stedim's price fluctuation is very steady at this time. Calculation of the real value of Sartorius Stedim Biotech is based on 3 months time horizon. Increasing Sartorius Stedim's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sartorius stock is determined by what a typical buyer is willing to pay for full or partial control of Sartorius Stedim Biotech. Since Sartorius Stedim is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sartorius Stock. However, Sartorius Stedim's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical
Market 197.2
Real 162.49
Hype 197.2
Naive 196.69
The intrinsic value of Sartorius Stedim's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sartorius Stedim's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sartorius Stedim Biotech helps investors to forecast how Sartorius stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sartorius Stedim more accurately as focusing exclusively on Sartorius Stedim's fundamentals will not take into account other important factors:
Sartorius Stedim Biotech is presently projected to have takeover price of 21.77 B with market capitalization of 36.27 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sartorius Stedim fundamentals before making investing decisions based on enterprise value of the company
About 70.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Sartorius Stedim Biotech had 6:1 split on the 6th of May 2016. Sartorius Stedim Biotech is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.
One of the ways to look at asset utilization of Sartorius is to check how much profit was generated for every dollar of assets it reports. Sartorius Stedim Biotech exercises its assets roughly 0.0313 %, realizing 0.0313 cents for each dollar of assets held by the company. A flourishing asset utilization indicates the company is being more effective with each dollar of assets it has. In other words, asset utilization of Sartorius Stedim shows how effective it operates for each dollar spent on its assets.
Covid
Sartorius Stedim Ownership Allocation
The market capitalization of Sartorius Stedim is USD36.27 Billion. Sartorius Stedim Biotech has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 69.7 % of Sartorius Stedim outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the company is less than the current market value, you may not be able generate positive returns on investment in the long run.
Sartorius Stedim Profitability Analysis
The company reported the revenue of 2.74 B. Net Income was 309.7 M with profit before overhead, payroll, taxes, and interest of 1.83 B.
About Sartorius Stedim Valuation
The stock valuation mechanism determines Sartorius Stedim's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Sartorius Stedim Biotech based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sartorius Stedim. We calculate exposure to Sartorius Stedim's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sartorius Stedim's related companies.
When running Sartorius Stedim's price analysis, check to measure Sartorius Stedim's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sartorius Stedim is operating at the current time. Most of Sartorius Stedim's value examination focuses on studying past and present price action to predict the probability of Sartorius Stedim's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sartorius Stedim's price. Additionally, you may evaluate how the addition of Sartorius Stedim to your portfolios can decrease your overall portfolio volatility.